Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: TNBC - Triple-Negative Breast Cancer Clear all
Recruiting No phase listed Observational
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 11:10 PM EDT
Suspended Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions
Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Rucaparib, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
Interventions
Rucaparib, Lucitanib, Sacituzumab govitecan
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions
BEZ235 + MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced May 21, 2026, 11:10 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
Interventions
Neratinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
Interventions
nab-Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced May 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, PD-L1 Negative
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
130
States / cities
Tucson, Arizona • Burbank, California • La Jolla, California + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
Interventions
COM701, COM701 with Opdivo (Nivolumab).
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced May 21, 2026, 11:10 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Interventions
ONC201
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
Interventions
Trilaciclib, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
35
States / cities
Tucson, Arizona • Burbank, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
XL102, Fulvestrant, Abiraterone, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced May 21, 2026, 11:10 PM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Onco4D Biodynamic Chemotherapy Selection Assay
Diagnostic Test
Lead sponsor
Animated Dynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Springdale, Arkansas • Palo Alto, California • Decatur, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions
Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Pembrolizumab, Vaccine Therapy
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Niraparib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Burbank, California • Duarte, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
LCL161, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
955
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced May 21, 2026, 11:10 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Interventions
Checkpoint Inhibitor, Immune
Drug
Lead sponsor
VastBiome
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Elizabethtown, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 21, 2026, 11:10 PM EDT